Immune Responses Alter Taste Perceptions: Immunomodulatory Drugs Shape Taste Signals during Treatments

Anthony Y. Huang

Department of Anatomy and Center for Integrated Research in Cognitive and Neural Science, Southern Illinois University School of Medicine, Carbondale, Illinois

Received July 3, 2019; accepted October 8, 2019

ABSTRACT

Considering that nutrients are required in health and diseases, the detection and ingestion of food to meet the requirements is attributable to the sense of taste. Altered taste sensations lead to a decreased appetite, which is usually one of the frequent causes of malnutrition in patients with diseases. Ongoing taste research has identified a variety of drug pathways that cause changes in taste perceptions in cancer, increasing our understanding of taste disturbances attributable to aberrant mechanisms of taste sensation. The evidence discussed in this review, which addresses the implications of innate immune responses in the modulation of taste transmission, focuses on the adverse effects on taste transmission from taste buds by immune modulators responsible for alterations in the perceived intensity of some taste modalities. Another factor, damage to taste progenitor cells that directly results in local effects on taste buds, must also be considered in relation to taste disturbances in patients with cancer. Recent discoveries have provided new insights into the pathophysiology of taste dysfunctions associated with the specific treatments.

SIGNIFICANCE STATEMENT

The paradigm that taste signals transmitted to the brain are determined only by tastant-mediated activation via taste receptors has been challenged by the immune modification of taste transmission through drugs during the processing of gustatory information in taste buds. This article reports the findings in a model system (mouse taste buds) that explain the basis for the taste dysfunctions in patients with cancer that has long been observed but never understood.

Introduction

Taste disorders such as ageusia (lack of taste), hypogeusia, and dysgeusia, particularly the inability to detect basic tastes, can have a substantial negative impact on general health and quality of life by affecting appetite and influencing food choices. Several clinical studies have reported that about 15%–55% of patients with cancer suffer from changes in taste perceptions (Kumar and Narang, 2011; Berking et al., 2014; Murtaza et al., 2017). The cause has been shown to be an innate immune response that appears to be a common factor in many diseases associated with gustatory dysfunction. Taste cells, which respond to the potential pathogen-associated molecular patterns (PAMPs), i.e., converted bacterial structures, are equipped with various immune signaling molecules, especially those associated with the innate defense response. Several laboratories have reported that taste cells express PAMP recognition receptors, such as Toll-like receptors (TLRs) and their corresponding adaptor proteins, including cytokines, chemokines, and their receptors (Wang et al., 2007, 2009; Cohn et al., 2010; Feng et al., 2012; Huang and Wu, 2016). Furthermore, studies in recent years have described an emerging role for receptors, corresponding to that of pathogens and proinflammatory cytokines, in the subsequent regulation of taste bud functions (Wang et al., 2007, 2009; Shi et al., 2012; Feng et al., 2015). In rodent-based model studies, the innate immune response was not only critical for maintaining the structural integrity of taste buds (Kim et al., 2012; Feng et al., 2014) but also correlated with circumstances within taste buds, whereby taste signal transmissions were altered during the processing of gustatory information (Huang and Wu, 2016). Although the causes of taste disturbances are multifactorial, defective peripheral taste signaling resulting in stasis taste sensations is a common pathophysiological contributor to taste disorders.
The division of the sense of taste into several basic taste modalities in human (sweet, sour, bitter, salty, umami, and possibly fatty) yields nutritive information, influences palatability, and aids avoidance of harmful substances from the environment. Taste buds, the peripheral taste organs, are small clusters of specialized epithelial cells on the tongue and in the oral cavity. Initiation of taste sensations is coordinated through activation of taste receptors expressed on specific taste cells, which release transmitters during gustatory stimulation to stimulate primary afferent sensory fibers that carry the gustatory information to the brain (Finger et al., 2005; Huang et al., 2007; Taruno et al., 2013). Although the sense of taste serves the critical function of guiding dietary selection and avoiding toxins and indigestible materials, intriguingly, taste perceptions may be altered by medications (Heath et al., 2006; Kumar and Narang, 2011; Berking et al., 2014; Murtaza et al., 2017; Frampton and Basset-Séguin, 2018). Indeed, human taste thresholds are altered by selective serotonin reuptake inhibitors such as Prozac (Heath et al., 2006; PDR Staff, 2010). Furthermore, our previous study that investigated the taste signal transmission in support of the rodent research demonstrated that serotonin (5-HT) provides negative paracrine feedback on intercellular signaling (Huang et al., 2009). Conceivably, altered taste perceptions seen in patients with affective disorders may reflect an actual change in the peripheral taste organs in the gustatory system. The concept that the functions of taste buds are responsible for establishing taste thresholds in both health and disease is beginning to be elucidated.

### Intercellular Interactions within Taste Buds

In humans, there are about 5000 taste buds in the oral cavity. They are located mostly on the dorsal surface of the tongue but also on the palate and epiglottis. Their apical tips directly contact the external environment in the oral cavity via taste pores. In addition to about 100 elongated taste cells extending from the base of the taste bud to its apex, there are a few taste progenitor cells at the base of the taste bud. An identification scheme that integrates the characteristics of ultrastructures and expression of functional proteins involved in taste transduction recognizes four morphotypes: type I, type II, type III cells, and basal cells, sometimes termed type IV. Initiation of taste sensations consists of a highly complex set of cell-to-cell interactions within taste buds, via transmitters, prior to propagation of signals to the brain (Finger et al., 2005; Herness and Zhao, 2009; Huang et al., 2007, 2009). For additional details regarding their roles in taste, there are several excellent reviews on this topic (Chaudhari and Roper, 2010; Roper and Chaudhari, 2017).

Type I cells comprise more than half the total number of cells in a taste bud and enwrap adjacent taste cells with extended cytoplasmic processes. Type I cells, with glial-like functions, express a surface-bound enzyme, ecto-ATPase, to eliminate the extracellular ATP (Finger et al., 2005; Bartel et al., 2006). As well, type I cells possess ion channels involved in K⁺ homeostasis within the internal environment of taste buds (Dvoryanchikov et al., 2009). Type I cells responsible for salt taste remain to be confirmed by future studies, but Vandenbeuch et al. (2008) have reported Na⁺ transduction mechanisms in type I cells that are implicated in salt taste. Moreover, type I cells synthesize and express the enzyme of γ-aminobutyric acid (GABA) (Dvoryanchikov et al., 2011; Huang et al., 2011a) and secrete GABA during peptidergic stimulations (Huang and Wu, 2018).

Type II cells, approximately one-third of cells in a taste bud, express G protein-coupled receptors (GPCRs) for taste as well as downstream effectors such as phospholipase C (PLC) β2. GPCRs consist of heterodimers of the taste receptor type 1 family, i.e., T1R1, T1R2, and T1R3, for sweet and umami compounds, and the taste receptor type 2 family (T2Rs) for bitter compounds. Conceivably, type II cells respond to a variety of taste compounds including sweet, bitter, and umami stimuli (Yang et al., 2000; Medler et al., 2003; Clapp et al., 2006; DeFazio et al., 2006; Tomchik et al., 2007; Huang et al., 2009; Deshpande et al., 2010; Yoshida et al., 2010; Roper and Chaudhari, 2017). Additionally, the expression of transient receptor potential cation channel subfamily M member 5 (TRPM5), essential for initiating taste signal transmission, is found on type II cells (Tulavera et al., 2008; Ishimaru and Matsunami 2009; Huang and Roper, 2010). Upon gustatory stimulation, type II cells secrete ATP via gap junction hemichannels (Huang et al., 2007; Huang and Roper, 2010 Romanov et al., 2007) or voltage-gated ion channels (Taruno et al., 2013). Furthermore, ATP excites gustatory sensory afferent fibers through P2X receptors (Finger et al., 2005; Huang et al., 2011b; Vandenbeuch et al., 2015) and, acting as a paracrine transmitter, ATP also excites adjacent type III taste cells (Huang et al., 2009).

Type III cells, about 20% of cells in a taste buds, form the synaptic contacts with peripheral nerve terminals (Yang et al., 2000; Yee et al., 2001; Huang and Wu, 2015). A sensation scheme that integrates responses to acid (sour) taste stimuli as well as carbonated solutions (Huang et al., 2006, 2008b; Chandrashekar et al., 2009; Chang et al., 2010) and high concentrations of KCl (Huang et al., 2007; Oka et al., 2013) generally indicates that type III cells are responsible for signaling these sensations. Transmitters secreted from type III cells, including 5-HT (Huang et al., 2007), norepinephrine (NE) (Huang et al., 2008a), and GABA (Huang et al., 2011a), mediate inhibitory feedback to type II cells during the processing of gustatory information in taste buds (Huang et al., 2009; Dvoryanchikov et al., 2011; Roper and Chaudhari, 2017). Given the importance of signal transmission in taste buds, the modulation of gustatory information in peripheral sensory organs is attributable to cell-to-cell communication through purinergic, aminergic, and GABAergic signaling.

### The Significance of Identifying the Transmitters in Taste Buds

One of the striking mechanisms of taste sensations is the intercellular communication that is generally associated with taste transmitters. Taste sensations require initial compilations of cell-to-cell interactions prior to transmission of a coherent output to excite primary gustatory afferent fibers and the resulting dispatch of signals to the brain (Herness and Zhao, 2009; Huang et al., 2009; Jaber et al., 2014). This information processing involves cell-to-cell communication via transmitters such as ATP, 5-HT, NE, and GABA within the taste bud. Cell-to-cell signaling is basic to other sensory organs, most notably the retina (Rogers et al., 2005; Palacios-Prado et al., 2009;
Wurm et al., 2010), but also the carotid body (Xu et al., 2003; Nurse, 2005; Eyzaguirre, 2007) and elsewhere. The importance of knowing the transmitters involved in taste perceptions cannot be underestimated. Current strategies to modify taste use as a basis molecules that 1) act on taste GPCRs to enhance sweetness and depress bitterness (Xu et al., 2004; Clapp et al., 2006; Delay et al., 2006; Chaudhari et al., 2009; Kinnamon and Vandenbeuch 2009; Treesukosol et al., 2009; Ohkuri et al., 2009) or that 2) act on effectors immediately downstream of taste GPCRs, such as TRPM5 (de Araujo et al., 2008; Devantier et al., 2008; Talavera et al., 2008; Ishimaru and Matsumami 2009; Long et al., 2010) and inositol 1,4,5-trisphosphate receptor (IP3R) (Hisatsune et al., 2007). Taste modification by manipulation of transmission within the taste bud has seen many new developments, controversies, and clarifications in the past decade. The implications for diet selection (such as during aging), compliance in taking medications (namely, by suppressing drug bitterness), and as a result enhancement of the quality of life are just beginning to be investigated.

Chemesthetic Regulations of Taste Sensations

Generally speaking, somatosensory branches of the trigeminal (CN V), glossopharyngeal (CN IX), and vagus (CN X) cranial nerves innervate the epithelium in which taste buds are located. The terminals of these somatosensory fibers often surround taste buds, indicating the close association of the gustatory and somatosensory systems. Chemesthesia is the general chemical sensitivity of the skin and mucous membranes in the oronasal cavities and is perceived as pungency, irritation, or heat. Chemesthetic activators, such as capsaicin and a variety of other strong oral irritants, act on these populations of sensory fibers via transient receptor potential vanilloid 1 (TRPV1) receptors (Ishida et al., 2002; Roper, 2014).

The notion that taste sensations consists only of gustatory information generated by taste stimuli themselves in taste buds may be too simplistic. Environmental changes in the mouth, such as temperature, may alter taste sensations. For instance, the temperature highly influences the pungency of foods and beverages, so that their acidity and, for beverages, their carbonation are altered when they are consumed. Considering that peripheral sensory nerve terminals that have ability to release stored transmitters (e.g., calcitonin gene–related peptide (CGRP) and substance P (SP)) onto taste cells, this modulation was interpreted as being produced indirectly by the axon reflex (Wang et al., 1995; Ishida et al., 2002; Simon et al., 2003). Furthermore, using electrophysiology (Simon et al., 2003), Ca2+ imaging (Huang and Wu, 2015, 2018), and psychophysical testing (Kapau and Dando, 2017), several studies investigating polymodal nociceptors in taste buds support the notion that oral nociceptive inputs are modulators of gustatory transmission, and their contributions influence the perceived intensity of some taste modalities. These findings extended the results of a previous study, which showed that the CGRP- and SP-immunoreactive nerve fibers innervating the epithelium containing taste buds coexpress TRPV1 in vallate taste papillae (Ishida et al., 2002). Recent imaging results reported that their stored transmitters, CGRP and SP, acting on taste cells via their corresponding receptors elicit secretion of signaling molecules and, as a result, shape taste signals within taste buds during gustatory stimulations (Huang and Wu, 2015, 2018). Collectively, one of the brilliant features of the peptidergic action within taste buds is the important chemesthetic regulation of taste signal transmission that, theoretically, may relate to the processing of the gustatory information. In sum, sensations experienced in the mouth affect the taste signal transmission, and thus influence food choices.

Parenthetically, recent studies reported a specific subset of TRPV1-expressing neurons that preferentially coexpress TLR7 (Helley et al., 2015) and that are equipped with diverse intracellular molecules responsible for the immune response (Kim et al., 2011). Conceivably, despite CGRP and/or SP shaping of taste signals during the processing of gustatory information in taste buds, the innate immune response may also regulate taste responses indirectly via peptidergic modulations within taste buds. Although intriguing, this hypothesis needs further investigation. Figure 1 summarizes this postulated scenario in the schematic taste bud.

Mechanisms of Immunity within Taste Buds

Clinically, one of the striking features of diseases such as upper respiratory viral infection, oral cavity infection, and viral hepatitis is a loss of taste ability that is characterized by increased detection and recognition thresholds for various taste stimuli, such as bitter, sour, salty, and sweet compounds (Henkin et al., 1972, 1975; Goddspeed et al., 1987; Graham et al., 1995; Weiffenbach et al., 1995; Cullen and Leopold, 1999; Gomez et al., 2004). Furthermore, patients with such cancers as basal cell carcinoma express similar complaints about taste impairments (Kumar and Narang, 2011; Berking et al., 2014; Yang et al., 2015; Frampton and Basset-Séguin, 2018). Notably, the inflammatory state of advanced diseases appears to play a role in infectious diseases as well as in cancers associated with taste disturbances (Kumar and Narang, 2011; Murtaza et al., 2017). Despite the importance/severity of the clinical state generally associated with taste dysfunctions, little information has been generated regarding the interaction between immunity and taste.

Taste bud cells, which face great challenges in the oral cavity from potential PAMPs such as lipopolysaccharide, a major component of the outer membrane of bacteria, are equipped with various inflammatory mechanisms associated with the innate immune response (Wang et al., 2007, 2009; Shi et al., 2012; Feng et al., 2015). By detecting the presence of TLRs in taste buds using reverse transcription–polymerase chain reaction and immunohistochemistry, previous findings have shown that TLRs 2, 3, 4, and 7 are expressed in a subset of taste cells (Wang et al., 2009; Huang and Wu, 2016). Stimulating TLRs produces proinflammatory cytokines and chemokines, such as interferon (IFN)-α, IFN-γ, IFN-inducible protein-10 (IP-10), interleukin (IL)-6, IL-10, IL-12, or tumor necrosis factor-α (TNF) (Hemmi et al., 2002; Oda and Kitano, 2006; Kawai and Akira, 2007; Brikos and O’Neill, 2008; Huang et al., 2014). Furthermore, recent studies reported the cascade of cytokine signaling pathways, such as changes in gene expression, that affect taste bud functions. For instance, activation of taste tissue via the IFN-γ receptor (IFNGR1), most probably on subsets of type II and type III cells, results in the phosphorylation of some transcription factors and the expression of IFN-inducible genes. As a result, the process of apoptosis is facilitated, as well as the increase of the number of
dead taste cells. These results suggest that interferon-induced cell death in taste buds may cause abnormal taste cell turnover (Wang et al., 2007, 2009; Cohn et al., 2010; Feng et al., 2012). Conversely, Feng et al. (2014) reported that a specific subset of taste cells secretes IL-10, which is consistent with a role in maintaining structural integrity of taste buds via an increase in the number of taste bud cells as well as the size of taste buds. Collectively, the immune response triggered by TLR activation contributes to taste dysfunction, which is associated with significant reductions in the sizes of peripheral taste organs, taste buds, and numbers of T1R- and T2R-expressing cells per taste bud (Murtaza et al., 2017).

**Immunomodulatory Drugs, Such as Imiquimod, Shape the Signal Outputs That Taste Buds Transmit to the Brain**

A medication sometimes causes changes in the body’s ability to recognize taste sensations (Kumar and Narang, 2011; Berking et al., 2014; Yang et al., 2015; Frampton and Basset-Séguin, 2018). Roughly, drugs may stimulate interactions between the innate immune response and the taste signal transmission, and thus modulate taste. Imiquimod, acting as an immune response modifier approved by the US Food and Drug Administration (FDA) for the treatment of basal cell carcinoma, acts on tumor cells via TLR7 to promote T cell-mediated apoptosis, and thus induces the production of interferon and other cytokines (Imbertson et al., 1998; Miller et al., 1999; Dahl, 2000; Schön et al., 2003; Heil et al., 2003, 2004; Kim et al., 2011). Strictly speaking, TLR7, a pattern-recognition receptor that recognizes PAMPs, initiates the innate immune response (Heil et al., 2004; Krieg and Vollmer, 2007; Kim et al., 2011; Hwang et al., 2014), which results in the production of proinflammatory cytokines, including IFN-α and TNF-α (Hemmi et al., 2002; Schön et al., 2003). Feng et al. (2012) have recently confirmed that taste cells express high levels of TNF-α. Indeed, during cancer treatments, imiquimod initiates proinflammatory cytokine pathways associated with loss of taste perceptions, as reported by Kumar and Narang (2011).

By using chimeric receptor approaches and immunohistochemistry, previous researchers have reported that TLR7, instead of localizing on the cell surface like regular TLRs, is completely localized in such intracellular compartments as endosomes or lysosomes (Lee et al., 2003; Akira and Takeda, 2004; Nishiya et al., 2005; Oda and Kitano, 2006; Kim et al., 2011). Imiquimod would enter the cells through the cell-surface membrane to access TLR7, which is localized in intracellular compartments, and to target PLC or other intracellular molecules (Cocco et al., 2001a,b; Suh et al., 2008; Grinberg et al., 2009). As in the mechanism of the brain-immune communication pathway (Quan and Banks, 2007), if imiquimod was able to enter the circulation directly and reach the gustatory epithelium containing taste buds, where small molecules could penetrate into the taste bud from the mucosa to influence activities of taste cells, several taste bud cell types, including type II and type III cells that have been shown to express TLR7 (Wang et al., 2009), would therefore be able to respond directly (Huang and Wu, 2016). Alternatively, proinflammatory cytokines and other soluble mediators could enter the circulation and...
reach the gustatory epithelia containing taste buds. Remarkably, despite the results of the previous study which showed the robust imiquimod-elicited Ca\(^{2+}\) responses seen in the dorsal root ganglion neurons (Kim et al., 2011), our group recently confirmed that imiquimod elicited PLC-dependent Ca\(^{2+}\) transients in the taste cells, most probably in type III cells (Huang and Wu, 2016), which is evidence for direct effects of systemic imiquimod administration in taste buds. Unexpectedly, considering that TLR7 is found in type II and type III cells, the direct activation is improbable because loxoribine, an agonist of TLR7, failed to trigger Ca\(^{2+}\) transients in taste cells. Therefore, the mechanisms of imiquimod-elicited Ca\(^{2+}\) signaling cascade remain an enigma, but imiquimod appears to activate PLC either directly or indirectly by binding to a second messenger. Furthermore, using Ca\(^{2+}\) imaging with cellular biosensors to test whether imiquimod shapes the final taste signal output transmitted from taste buds to the brain, our laboratory was able to obtain reliable results that imiquimod triggers type III cells to secrete 5-HT, which then provides negative feedback to adjacent type II cells to shape the taste signals (Huang et al., 2007; Huang and Wu, 2016).

A summary of the transmitter profile and taste signaling characteristics can be found in Roper and Chaudhari (2017). Serotonin-inhibitory signaling within taste buds, which shapes peripheral taste signals during the processing of gustatory information has been reported in human subjects (Heath et al., 2006) and rats (Jaber et al., 2014). Specifically, the net effect of imiquimod (10 \(\mu M\)), via initiated serotonergic inhibition within taste buds, reduced taste-evoked release of ATP (Huang and Wu, 2016). Considering the differences in methods and materials in these studies, the results are quite consistent. These results suggest the immune modulation of the processing of the gustatory information. Accordingly, these data suggest that the drug approved for the treatment of basal cell carcinoma, which causes taste disturbances by initiating the innate immune response (http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM252892.pdf; Kumar and Narang, 2011; Berking et al., 2014), alters taste signal transduction and transmission during processing of the gustatory stimulation. Parenthetically, this same resource reported that systemic absorption of imiquimod across the affected skin of human subjects generated mean peak serum concentrations ranging from 0.5 to 15 \(\mu M\), indicating that the mechanism of the taste-immune communication pathway may exist in the gustatory system. Figure 2 summarizes this postulated scenario in the schematic taste bud.

**Disruption of Taste Progenitor Cells Alters Taste Sensations**

Taste disturbance has also been reported in patients treated with vismodegib, another drug approved by the FDA for the treatment of basal-cell carcinoma (Berking et al., 2014; Yang et al., 2015; Frampton and Basset-Séguin, 2018). The notion
that the alterations in human taste perceptions associated with vismodegib-induced taste disturbances are most probably due to the aberrant taste cell turnover and the integrity of taste bud functions would be straightforward. During embryogenesis and development, hedgehog controls epithelial and mesenchymal interactions in many tissues, and is a key regulator of cell growth and differentiation, respectively. Binding of hedgehog on its receptor patched homolog 1 (PTCH1) as a tumor suppressor prevents PTCH1-mediated inhibition of signaling by smothened homolog (SMO). Initiation of SMO signaling results in the activation of downstream transcription factors, such as glioma-associated proteins, which control expression of hedgehog target genes (Amin et al., 2010). Thus, either inactivation of PTCH1 or constitutive activation of SMO results in substantial increase in the number of undifferentiated basal cells. Conceivably, total SMO inhibition by vismodegib, an aggressive blocker of smothened homologue, is a therapeutic option in patients with basal cell carcinoma (Amin et al., 2010; Frampton and Basset-Séguin, 2018). Recently, Yang et al. (2015) identified the pathway responsible for taste changes among cancer patients treated with vismodegib. Using a mouse model to simulate the effect of vismodegib in treated patients, they found that blocking the hedgehog signaling pathway resulted in profound alternations in taste bud structure and function as well as gustatory neural transduction, thus facilitating our understanding of alterations in vismodegib-induced taste perceptions in cancer patients. Furthermore, Kumari et al. (2015) reported similar findings: In a mouse model, use of LDE225, an inhibitor of the hedgehog pathway, resulted in disruption of taste progenitor cells and alteration of taste perceptions.

In spite of the changes in taste signal transmission attributable to the effects of the immune response as a mechanism, immuimod may also trigger PLC activation in the Golgi apparatus and nucleus (Cocco et al., 2001a,b; Suh et al., 2008; Grinberg et al., 2009), in which a variety of nuclear events occurs, including mRNA export, DNA repair, and gene transcription (Irvine 2003; Faenza et al., 2008, 2013). Indeed, in modern research systems, such as in vitro cell culture (Aisiku et al., 2011) and rodent models (Montaña et al., 2012), nuclear PLCβ, known as the abundantly represented family of isozymes in nuclei, has been demonstrated to participate directly in controlling the cell cycle, in which there is a direct effect on G1 progression (Cocco et al., 2004; Faenza et al., 2013). Conceivably, acting as a potent cell autonomous inhibitor of oncoenic hedgehog signaling, which is crucial to taste cell turnover (Gruber et al., 2014; Castillo et al., 2014; Yang et al., 2015), immuimod may also trigger local effects in taste buds. Hence, it is a feasible explanation that activating the immune responses causes either the interruption of taste cell turnover or the modulation of taste signal transmission, and thus the alterations in taste perceptions. However, without additional experimental results, the discussion is largely speculative.

Conclusions

Recent studies have provided evidence supporting the notion that the innate immune response alters taste sensations and provides a novel approach to the investigation of taste disturbances. (Wang et al., 2007, 2009; Cohn et al., 2010; Feng et al., 2012; Berking et al., 2014; Yang et al., 2015; Frampton and Basset-Séguin, 2018). Furthermore, these results offer new insights into the mechanisms underlying the therapeutic effects of immuimod on taste disturbances at pharmacologic doses (micromolar and higher) and, thus, as a taste sensation inhibitor.

This review has also highlighted the feasibility of a novel area of taste dysfunctions that has the potential to enhance health-related research. The characterization of local transmitters released from taste cells themselves and their aberrant effects caused by inflammation in the taste bud is essential not only for basic understanding of gustatory afferent excitation but also for potential clinical applications. These include development of taste modifiers for potential use in the management of obesity (Overberg et al., 2012), compliance in taking medications (particularly in pediatrics), and pharmaceutical development in the context of diminished taste sensation or ageusia related to age (Mistretta, 1984) or chemotherapy (Bernhardson et al., 2008; Pribitkin et al., 2003; Yamashita et al., 2006).

Acknowledgments

The author would like to acknowledge Cell Symposia and their conference “Neuro-Immune Axis: Reciprocal Regulation in Development, Health, and Disease” at which this work was presented.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Huang.

References


Address correspondence to: Dr. Anthony Y. Huang, Department of Anatomy, 1135 Lincoln Drive, Rm 2069 Life Science III BLDG, Southern Illinois University School of Medicine, Carbondale, IL 62901. E-mail: nhuang@siu.edu